Document Type
Journal Article
Publisher
Elsevier Inc
School
School of Medical and Health Sciences
RAS ID
25387
Funders
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Science and Industry Endowment Fund
Dementia Collaborative Research Centres
McCusker Alzheimer's Research Foundation
National Health and Medical Research Council
Yulgilbar Foundation
Cooperative Research Centre (CRC) for Mental Health
Yulgilbar Alzheimer's Research Program
CRC for Mental Health
Abstract
Introduction
High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia.
Method
Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness.
Results
Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months.
Discussion
Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.
DOI
10.1016/j.dadm.2017.05.006
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.
Comments
Harrington K.D., Lim Y.Y., Ames D., Hassenstab J., Laws S.M., Martins R.N., Rainey-Smith S., Robertson J., Rowe C.C., Salvado O., Doré V., Villemagne V.L., Snyder P.J., Masters C.L., Maruff P. (2017). Amyloid-β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 8(1), 156-164.
https://doi.org/10.1016/j.dadm.2017.05.006